Health Care [ 9/12 ] | Pharmaceuticals [ 57/73 ]
NASDAQ | Common Stock
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease.
Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 23, 25 | -0.58 Increased by +19.44% | -0.31 Decreased by -87.10% |
| Mar 17, 25 | -0.62 Increased by +26.19% | -0.70 Increased by +11.43% |
| Nov 6, 24 | -0.72 Increased by +1.37% | -0.64 Decreased by -12.50% |
| Aug 7, 24 | -0.59 Increased by +29.76% | -0.83 Increased by +28.92% |
| May 8, 24 | -0.72 Increased by +17.24% | -0.85 Increased by +15.29% |
| Mar 19, 24 | -0.84 Increased by +40.43% | -0.83 Decreased by -1.20% |
| Nov 8, 23 | -0.73 Increased by +44.27% | -0.91 Increased by +19.78% |
| Aug 8, 23 | -0.84 Increased by +36.84% | -0.90 Increased by +6.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -17.56 M Increased by +19.56% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -18.66 M Increased by +25.86% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -21.73 M Increased by +1.25% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -17.77 M Increased by +29.78% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -21.83 M Increased by +17.07% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -25.16 M Increased by +33.68% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -22.00 M Increased by +44.18% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -25.30 M Increased by +36.64% | Decreased by N/A% Decreased by N/A% |